Literature DB >> 33750894

Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.

Jianfu Zhou1,2,3, Yuliang Wang3, Dinglan Wu4, Shusheng Wang1, Zhiqiang Chen1, Songtao Xiang5, Franky Leung Chan6.   

Abstract

Castration-resistant prostate cancer (CRPC) almost invariably occurs after androgen-deprivation therapy (ADT) for the advanced metastatic disease. It is generally believed that among multiple mechanisms and signaling pathways, CRPC is significantly driven by the reactivation of androgen receptor (AR) signaling in ADT-treated patients with castrate levels of androgen, partially at least mediated by the androgen biosynthesis within the tumor, also known as intratumoral or intraprostatic androgen biosynthesis. Steroidogenic enzymes, such as CYP11A1, CYP17A1, HSD3B1, AKR1C3 and SRD5A, are essential to catalyze the conversion of the initial substrate cholesterol into potent androgens that confers the CRPC progression. Accumulating evidences indicate that many steroidogenic enzymes are upregulated in the progression setting; however, little is known about the dysregulation of these enzymes in CRPC. Orphan nuclear receptors (ONRs) are members of the nuclear receptor superfamily, of which endogenous physiological ligands are unknown and which are constitutively active independent of any physiological ligands. Studies have validated that besides AR, ONRs could be the potential therapeutic targets for prostate cancer, particularly the lethal CRPC progression. Early studies reveal that ONRs play crucial roles in the transcriptional regulation of steroidogenic enzyme genes. Notably, we and others show that three distinct ONRs, including liver receptor homolog-1 (LRH-1, NR5A2), steroidogenic factor 1 (SF-1, AD4BP, NR5A1) and estrogen-related receptor α (ERRα, NR3B1), can contribute to the CRPC progression by promotion of the intratumoral androgen synthesis via their direct transcriptional regulation on multiple steroidogenic enzymes. This review presents an overview of the current understanding on the intratumoral androgen biosynthesis in CRPC, with a special focus on the emerging roles of ONRs in this process.

Entities:  

Year:  2021        PMID: 33750894     DOI: 10.1038/s41388-021-01737-1

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  77 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

Review 3.  Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer.

Authors:  Zachery R Reichert; Maha Hussain
Journal:  Cancer J       Date:  2016 Sep/Oct       Impact factor: 3.360

Review 4.  Androgen synthesis in prostate cancer: do all roads lead to Rome?

Authors:  Ryan Stuchbery; Patrick J McCoy; Christopher M Hovens; Niall M Corcoran
Journal:  Nat Rev Urol       Date:  2016-11-08       Impact factor: 14.432

5.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

6.  The androgen axis in recurrent prostate cancer.

Authors:  James L Mohler; Christopher W Gregory; O Harris Ford; Desok Kim; Catharina M Weaver; Peter Petrusz; Elizabeth M Wilson; Frank S French
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

7.  Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

Authors:  S E Barrie; G A Potter; P M Goddard; B P Haynes; M Dowsett; M Jarman
Journal:  J Steroid Biochem Mol Biol       Date:  1994-09       Impact factor: 4.292

8.  Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy.

Authors:  J Geller; J D Albert; D A Nachtsheim; D Loza
Journal:  J Urol       Date:  1984-10       Impact factor: 7.450

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 10.  Mechanisms of resistance in castration-resistant prostate cancer (CRPC).

Authors:  Thenappan Chandrasekar; Joy C Yang; Allen C Gao; Christopher P Evans
Journal:  Transl Androl Urol       Date:  2015-06
View more
  6 in total

Review 1.  Estrogen-related receptor alpha in select host functions and cancer: new frontiers.

Authors:  Harmit S Ranhotra
Journal:  Mol Cell Biochem       Date:  2022-02-09       Impact factor: 3.396

2.  The HeyL-Aromatase Axis Promotes Cancer Stem Cell Properties by Endogenous Estrogen-Induced Autophagy in Castration-Resistant Prostate Cancer.

Authors:  Qimei Lin; Jiasong Cao; Xiaoling Du; Kuo Yang; Yongmei Shen; Weishu Wang; Helmut Klocker; Jiandang Shi; Ju Zhang
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

3.  Hijacking Sexual Immuno-Privilege in GBM-An Immuno-Evasion Strategy.

Authors:  Martyn A Sharpe; David S Baskin; Amanda V Jenson; Alexandra M Baskin
Journal:  Int J Mol Sci       Date:  2021-10-12       Impact factor: 5.923

Review 4.  Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?

Authors:  Gio Fidelito; Matthew J Watt; Renea A Taylor
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

5.  Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer.

Authors:  Mark D Long; Justine J Jacobi; Prashant K Singh; Gerard Llimos; Sajad A Wani; Aryn M Rowsam; Spencer R Rosario; Marlous Hoogstraat; Simon Linder; Jason Kirk; Hayley C Affronti; Andries Bergman; Wilbert Zwart; Moray J Campbell; Dominic J Smiraglia
Journal:  Cell Rep       Date:  2021-12-14       Impact factor: 9.423

6.  CYP1B1-catalyzed 4-OHE2 promotes the castration resistance of prostate cancer stem cells by estrogen receptor α-mediated IL6 activation.

Authors:  Qimei Lin; Jiasong Cao; Xiaoling Du; Kuo Yang; Xu Yang; Zhixian Liang; Jiandang Shi; Ju Zhang
Journal:  Cell Commun Signal       Date:  2022-03-15       Impact factor: 5.712

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.